Bionano Genomics (BNGO) Total Debt (2017 - 2023)

Bionano Genomics has disclosed Total Debt across 7 years of filings, most recently posting $10.0 million for Q3 2023.

• Total Debt for Q3 2023 came in at $10.0 million, up 7.49% year-over-year; the trailing twelve-month figure through Sep 2023 was $10.0 million (up 7.49% YoY), and the FY2022 annual result was $9.4 million, changed N/A from the prior year.
• Total Debt came in at $10.0 million for Q3 2023 at Bionano Genomics, roughly flat from $10.0 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $20.1 million in Q4 2019 to a low of $9.2 million in Q2 2022.
• The 5-year median for Total Debt is $15.7 million (2020), against an average of $14.3 million.
• Across the five-year window, Total Debt jumped 122.44% in 2019 and decreased 19.09% in 2020, its largest moves.
• Bionano Genomics' Total Debt stood at $20.1 million in 2019, then decreased by 18.72% to $16.3 million in 2020, then declined by 8.94% to $14.9 million in 2021, then slumped by 36.89% to $9.4 million in 2022, then grew by 6.59% to $10.0 million in 2023.
• The last three Total Debt figures came in at $10.0 million (Q3 2023), $10.0 million (Q2 2023), and $9.5 million (Q1 2023), per Business Quant data.